Breaking the Bottleneck of Anti-infective Drug R&D: Customized Pathogen-Specific Models Accelerate Preclinical Efficacy Evaluation

01、Service Overview

Preclinical evaluation of anti-infective drugs is plagued by core pain points such as strong host specificity of pathogens, insufficient predictability of traditional models, and low clinical translation rate. Jennio Bio provides customized anti-infective drug evaluation models. Through the construction of highly biomimetic infection models and a multi-dimensional efficacy evaluation system, we shorten the R&D cycle by more than 30% and significantly reduce the risk of clinical failure.

02、Our Services

1. Bacterial Infection Models
   • Staphylococcus aureus infection models: Diabetic wound infection. Rats are induced to develop diabetes with STZ followed by dorsal skin inoculation to simulate clinical recalcitrant infections; Endocarditis. Cardiac intubation and inoculation are performed to simulate clinical infective endocarditis. Evaluation indicators include colony counting, inflammatory factors (TNF-α/IL-6) and histopathology.
   • Streptococcus pneumoniae model: Upper respiratory tract infection model, used to evaluate the inhibitory effects of antibiotics on survival time extension, pulmonary bacterial load and inflammatory injury.

2. Viral Infection Models

• HBV model: rAAV-HBV mouse model. Tail vein inoculation of rAAV8-1.3HBV virus is conducted to simulate clinical chronic hepatitis B (HBV). Evaluation indicators: The antiviral efficacy of drugs is verified by detecting changes in serological viral markers (including HBsAg, HBV DNA, HBeAg, etc.) after administration.
• Rotavirus/Enterovirus model: SA11 virus amplification and plaque assay, applicable for the evaluation of oral antiviral drugs.

3. Fungal Infection Models

• Cryptococcus infection model: Central nervous system or pulmonary infection model. The antifungal efficacy is evaluated by measuring brain tissue fungal load and the degree of inflammatory infiltration.

4. Polymicrobial Infection and Drug Resistance Research

• ESKAPE multidrug-resistant bacterial infection: Combined with drug susceptibility tests (e.g., MIC determination) and in vivomodels to evaluate the breakthrough efficacy of new antibiotics.

03、Technology Platforms and Advantages

Technology Platforms

• Stable HBV model construction system: AAV virus with precise liver-targeting infection, with an infection success rate of >90%.
• Pseudovirus packaging platform: Supports the safe research of high-risk pathogens such as SARS-CoV-2 (BSL-2 certified).

Infrastructure

• SPF animal facility + ABSL-2 laboratory: Capable of conducting high-risk pathogen research, equipped with in vivoimaging systems, a variety of hematology testing instruments for detecting multiple virus-related indicators, ventilators and other equipment to support real-time efficacy monitoring.
• Titer detection: High viral titer to ensure model stability.

Differentiated Advantages

• Broad pathogen coverage: A full-chain evaluation platform supporting bacteria, viruses and fungi simultaneously.
• Clinical relevance: Model validity is verified by multiple assays including histopathology (HE staining), biochemical indicators and virological indicators.

04、Service Process

• Demand Communication: Customization of protocols for pathogen types, challenge infection sites and evaluation indicators.
• Model Execution and Monitoring: Real-time sharing of model establishment progress (e.g., DAI score, bacterial load).
• Data Delivery (7-14 days): Provision of GLP-aligned standard reports including raw data, statistical analysis and pathological sections.

05、Quality Control and Compliance

• Qualification certification: SPF animal facility certification, Laboratory Animal Use License.
• Quality control measures: Double-blind data review, third-party cross-validation (e.g., HBsAg detection compared with commercial kits).
• Compliance standards: Adherence to FDA/EMA guidelines for anti-infective drugs, with data traceable to original records.

06、Case Studies

Case 1: Efficacy of Azithromycin in a Streptococcus pneumoniae Infection Model

• Results:The treatment group showed a significant extension of survival time, a marked reduction in pulmonary bacterial load, and a significant decrease in serum IL-6, etc.
• Figures:Survival curve comparison, cytokine statistics of bronchoalveolar lavage fluid, histopathology.

View Full Case

Case 2: Evaluation of Staphylococcus aureus-infected Diabetic Wound Healing

• Results: The new dressing group achieved a 70% reduction in infected area, decreased purulent secretion and accelerated tissue healing.
• Figures: Wound area comparison, tissue HE staining (inflammatory score).

07、Cooperation Advantages

• Full-cycle support: From early pathogen screening to efficacy data packages for IND filing.
• Efficient delivery: The cycle of standard models is 30% faster than the industry average.
• Resource integration: A strain library with over 1000 strains, covering various drug-resistant strains and special pathogens, to quickly match research needs for specific pathogens.

08、FAQ

Q: Are non-mammalian infection models supported?

A: Only rodent (mouse/rat) and rabbit models are available; non-mammalian models are not covered for the time being.

Q: Can antibiotic resistance research be conducted?

A: We support the evaluation of ESKAPE strain drug resistance, and provide MIC determination and drug resistance gene PCR verification.

09、Laboratory Highlights

A 10,000-class clean animal facility supports the operation of high-risk pathogens, with a daily sample processing capacity of over 100.

An isolator filling platform ensures the sterility of viral preparations, in compliance with GMP-aligned standards.

View More

10、Contact Us

Consult Now:

• 3691125803@qq.com
• Tel: +86 18802035152
• Online Form: Get a customized proposal for free

Resource Download:

• Technical White Paper on Anti-infective Models
• GLP-aligned Experimental Procedure Manual